Compare MXE & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXE | SCLX |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | United States | United States |
| Employees | N/A | 34 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.9M | 52.5M |
| IPO Year | 1994 | N/A |
| Metric | MXE | SCLX |
|---|---|---|
| Price | $13.25 | $7.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.0K | ★ 71.1K |
| Earning Date | 01-01-0001 | 04-10-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $122.52 |
| Revenue Next Year | N/A | $186.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.21 | $4.20 |
| 52 Week High | $14.30 | $34.27 |
| Indicator | MXE | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 53.81 |
| Support Level | $12.66 | $7.73 |
| Resistance Level | $13.93 | $9.44 |
| Average True Range (ATR) | 0.22 | 0.77 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 61.79 | 67.04 |
Mexico Equity and Income Fund Inc. is a closed-end, non-diversified management investment company that aims for long-term capital appreciation and current income. It prominently invests in equity, convertible securities, and debt issued by Mexican companies, operating across various sectors. The fund benchmarks its performance against the Mexbol and MSCI Mexico Index. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.